Treatment Guesses Differed Between CBD and Placebo Periods in the SCI Pain Trial
Participants identified placebo more accurately than CBD in the spinal-cord-injury trial. A double-blind design did not establish that every participant remained equally uncertain throughout both periods.
The investigators assessed treatment guesses
After each treatment period, participants were asked whether they thought they had received CBD, placebo or were unsure, along with their confidence. The discussion reports CBD guessing around chance, while approximately 78% correctly identified placebo.
The result suggests an interpretive limit
Participants may form guesses from perceived benefit, adverse effects or other experiences. The study did not determine the contribution of each explanation. Accurate guessing can be a consequence of treatment experience as well as a possible contributor to expectations about subsequent ratings.
Blinding information qualifies rather than cancels the result
The trial’s randomized, masked crossover design still supplies evidence of a modest pain difference. The guessing pattern does not prove that expectations caused that entire difference or that CBD had no pharmacological effect. It does mean that formal masking procedures should not be equated with demonstrated uniform uncertainty. This distinction is especially useful when interpreting subjective outcomes: treatment allocation, participant belief and reported pain remain related but separately measured parts of the evidence.
Related analysis: the study’s broader findings and limitations.
